Skip to main content
TipRanks
Go Ultimate75% OFF

Sofwave (SOFW) AI Stock Analysis

6 Followers
IL:SOFW

Sofwave

(TASE:SOFW)

Select Model
Rating:86Outperform
Price Target:ILA 4,587.00â–²(24.55% Upside)
Action:reiterated
Date:11/10/26

Sofwave (IL:SOFW) earns a strong overall score of 86, driven primarily by its stellar financial performance and robust technical momentum. The company has successfully scaled its top line while pivoting to substantial profitability and positive cash flow, all backed by an unlevered balance sheet. Technically, the stock is in a confirmed uptrend, trading above all major moving averages with healthy, bullish indicators. The primary offsetting factor is its valuation; a P/E ratio of 33.95 indicates a premium pricing that reflects its high-growth profile but presents a moderate valuation risk.

Positive Factors
Revenue and Profitability TurnaroundStrong revenue expansion combined with a move into operating profitability indicates meaningful commercial progress and improving operating leverage. If sustained, this larger revenue base and high gross-margin profile can support reinvestment, strengthen market presence, and improve earnings resilience over the next several quarters.
Negative Factors
Recent Profitability Is Not Yet Proven Through CyclesThe profitability improvement is encouraging, but its short history makes durability an important execution risk. Sofwave must sustain demand growth and control costs after several loss-making years; any slowdown or expense increase could quickly weaken the newly established earnings profile.

Sofwave (SOFW) vs. iShares MSCI Israel ETF (EIS)

-10%0%10%20%30%40%50%60%70%IL:SOFW+27.00%EIS+10.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 1.34B
Dividend Yield
―
Average Volume (3M)
94.97K
Price to Earnings (P/E)
32.0
Beta (1Y)
0.67
Revenue Growth
25.84%
EPS Growth
1717.73%
Country
Israel
Employees
151
Sector
General
Sector Strength
55
Industry
Medical - Devices

Sofwave Business Overview & Revenue Model

Company Description

Founded in 2015, Sofwave Medical Ltd. is an Israeli company dedicated to developing cutting-edge ultrasound technology. This technology is employed for the non-invasive treatment of fine lines and wrinkles, with the company's reach extending to physi...

Sofwave Financial Statement Overview

Summary

Sofwave demonstrates exceptional financial health across the board. The company has scaled revenue dramatically to $111.9 million in the TTM period while maintaining stellar 74-76% gross margins. It has successfully pivoted to profitability, generating $12.0 million in TTM net income and $14.9 million in free cash flow. A negligible debt-to-equity ratio of 0.03 and a highly impressive 32.4% return on equity highlight a pristine balance sheet and efficient capital use.

Income Statement

90Very Positive

Balance Sheet

92Very Positive

Cash Flow

89Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue111.91M94.86M59.65M50.31M35.63M21.84M
Gross Profit85.01M70.27M45.34M37.48M26.33M16.24M
EBITDA15.70M9.39M-2.19M-6.61M-17.55M-6.43M
Net Income12.02M5.94M-4.55M-8.28M-19.53M-6.83M
Balance Sheet
Total Assets65.99M55.78M43.03M43.54M46.08M60.77M
Cash, Cash Equivalents and Short-Term Investments30.88M35.28M21.62M24.42M32.01M46.22M
Total Debt1.25M1.12M1.40M1.33M1.92M2.37M
Total Liabilities23.37M23.06M18.50M17.19M13.74M14.07M
Stockholders Equity42.62M32.72M24.53M26.34M32.34M46.70M
Cash Flow
Free Cash Flow14.92M14.51M-2.67M-6.71M-11.14M-2.92M
Operating Cash Flow15.69M15.08M-2.40M-6.31M-10.69M-2.10M
Investing Cash Flow-10.74M-1.15M254.00K409.00K-260.00K-982.00K
Financing Cash Flow-77.98K-469.79K-620.00K-1.72M-1.35M46.64M

Sofwave Technical Analysis

Technical Analysis SentimentPositive
Last Price3683.00

Price Trends

50DMA3441.00Positive
100DMA3698.98Negative
200DMA3831.05Negative

Market Momentum

MACD41.81Positive
RSI54.28Neutral
STOCH34.63Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:SOFW, the sentiment is Positive. The current price of 3683.00 is above the 20-day moving average (MA) of 3619.35, above the 50-day MA of 3441.00, and below the 200-day MA of 3831.05, indicating a neutral trend. The MACD of 41.81 indicates Positive momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 34.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:SOFW.

Sofwave Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IL:SOFW against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:SOFWIL:SOFW86OutperformILS 1.33B32.01――25.84%1717.73%
IL:BWAYIL:BWAY70OutperformILS 1.21B35.7213.07%―15.22%33.08%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-50%0%50%100%IL:SOFWIL:BWAYIL:ILXIL:ALMDIL:EPITIL:PLSMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:SOFW and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:SOFWSofwave Medical Ltd.3683.00734.0024.89%
IL:BWAYBrainsway 2969.00438.0017.31%
IL:ILXILEX Medical Ltd.4717.00-1849.73-28.17%
IL:ALMDAllmed Solutions Ltd.29.40-2.10-6.67%
IL:EPITEPITOMEE MEDICAL LTD246.60-475.50-65.85%
IL:PLSMPulsenmore464.20-1967.47-80.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026